SOPHiA Genetics Chief Medical Officer Sells 5,000 Shares Under Rule 10b5-1 Trading Plan

Insider Transaction Details and Trading Plan Mechanism

The disclosure filed on July 28, 2026, documents that Philippe Menu, serving as Chief Medical Officer of SOPHiA Genetics SA, executed a sale of 5,000 ordinary shares on July 27, 2026. According to the filing, the transaction was conducted pursuant to a duly adopted trading plan under Rule 10b5-1(c), a regulatory mechanism established under Securities Exchange Act Rule 10b5-1 that permits corporate insiders to establish predetermined arrangements for buying or selling company securities. Under this rule, insiders can schedule equity transactions in advance, which provides protection against allegations of trading while in possession of material nonpublic information, provided certain conditions are satisfied at the time of plan adoption.

The weighted average price at which the shares were sold was $5.6611 per share. The filing indicates that Menu undertakes to provide, upon written request to the company, security holders, or the Securities and Exchange Commission, full information regarding the number of shares sold at each of the separate prices within the disclosed range. This level of transparency is required under SEC guidelines when an insider executes multiple transactions at varying prices on the same day, allowing regulators and shareholders to assess the transaction's execution quality and timing across market conditions.

Share Price Range and Transaction Execution

Menu's share sale was not executed at a single price but rather across multiple transactions occurring on July 27, 2026, with individual prices ranging from $5.57 to $5.83 per share. This price range indicates that the insider's broker likely executed the sale over a period of time during the trading day or across multiple market conditions, which is typical when disposing of a meaningful volume of shares. The weighted average calculation reflects the blended result across all these separate executions, giving investors a clear picture of the net proceeds relative to the total number of shares sold.

The filing notes specifically that the price reported in Column 4 is a weighted average price, underscoring that no single transaction occurred at $5.6611. This disclosure mechanism ensures market participants understand the actual execution and prevents mischaracterization of the sale as occurring at a single point price. The variation between the low and high prices ($5.57 to $5.83) represents a range of approximately 4.7 percent, which may reflect normal intraday volatility or execution across different time periods during the trading session.

Beneficial Ownership Position Following the Sale

After the completion of the 5,000-share sale, Philippe Menu maintained a direct beneficial ownership position of 223,387 ordinary shares in SOPHiA Genetics SA. This remaining stake represents his ownership interest held directly in his own name, as opposed to any shares held indirectly through trusts, family members, or other entities. The filing does not indicate that Menu holds any additional shares through indirect ownership arrangements, though the form provides space for such disclosure if applicable.

The size of Menu's remaining stake indicates a substantial ongoing investment in the company he serves as Chief Medical Officer. The combination of his leadership role and significant share ownership may be viewed by investors as demonstrating alignment between his interests and those of other shareholders. However, the timing and nature of insider sales, even when executed under pre-arranged trading plans, are often monitored by market participants as potential signals regarding executives' confidence in the company's near-term prospects, though such interpretations remain matters of individual investor judgment.

Rule 10b5-1 Trading Plan Compliance Framework

The filing explicitly states that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). This regulatory framework permits corporate officers, directors, and major shareholders to establish predetermined trading schedules without facing accusations of trading on the basis of material nonpublic information. The rule requires that the plan be adopted when the insider is not in possession of material nonpublic information and that certain cooling-off periods and other conditions be satisfied.

By establishing a Rule 10b5-1 trading plan, Menu created a binding contractual arrangement that removes discretion from his day-to-day trading decisions, thereby reducing concerns that any individual sale might be timed to capitalize on confidential corporate developments. The SEC views such plans as important tools for insiders to manage their equity positions in a transparent and regulated manner. The filing indicates the plan was duly adopted, meaning it met all regulatory requirements at the time of its establishment, though the specific date of plan adoption and its initial parameters are not disclosed in this particular form.

Officer and Shareholder Status at SOPHiA Genetics

Philippe Menu's role as Chief Medical Officer of SOPHiA Genetics SA places him among the company's senior leadership team. The filing confirms he is an officer of the company and indicates he is not a director or a 10 percent owner. His position as CMO suggests he holds significant responsibility for the company's clinical and medical strategy, product development oversight, and regulatory compliance matters related to its genetic analysis and precision diagnostics platform. The title Chief Medical Officer typically indicates involvement in clinical validation, medical affairs, and clinical governance within life sciences and diagnostic companies.

Menu's beneficial ownership of 223,387 shares following this transaction represents a meaningful but non-controlling stake in the NASDAQ-listed company. This ownership level demonstrates ongoing confidence and participation in the company's equity, while the Rule 10b5-1 sale mechanism suggests he is managing his personal portfolio in accordance with applicable insider trading regulations. The combination of executive role and substantial shareholder position is common among senior managers at life sciences firms, where equity compensation and ownership are frequently used to align management incentives with shareholder returns.

Timing of Filing and Public Disclosure

The transaction was executed on July 27, 2026, and the related Form 4 filing was submitted to the Securities and Exchange Commission on July 28, 2026. This timing reflects the SEC's requirement that insiders file beneficial ownership reports within two business days of the transaction date. The filing was signed on July 28, 2026, by Elimara Brunetto, identified as attorney-in-fact for Philippe Menu, indicating that Menu authorized this individual to execute the filing on his behalf, which is a standard practice among corporate insiders managing multiple disclosure obligations.

The public disclosure of this transaction via SEC EDGAR filings ensures that all market participants have access to timely, standardized information regarding insider buying and selling activity at SOPHiA Genetics SA. Investors monitoring insider transactions can use this information as one data point among many when forming investment theses or assessing management sentiment regarding the company's prospects. The Form 4 filing requirement is designed to promote market transparency and help investors understand whether company insiders are accumulating or reducing their stakes in their employer.

No Derivative Securities Activity Reported

The filing includes a Table II section for reporting derivative securities, such as options, warrants, convertible securities, or other instruments that derive their value from underlying ordinary shares. However, no entries appear in Table II for Philippe Menu's account, indicating that this transaction involved no derivative securities. The Form 4 shows activity only in Table I, which covers non-derivative securities—in this case, ordinary shares of SOPHiA Genetics SA.

The absence of derivative activity in this disclosure does not provide information regarding whether Menu holds any unexercised stock options, warrants, or other derivative instruments acquired previously. Form 4 filings only report changes in beneficial ownership and derivative positions that occur during the reporting period, not the full inventory of all derivative securities an insider may hold. Investors seeking a comprehensive view of an insider's total derivative holdings would need to review proxy statements or other regulatory filings that provide complete beneficial ownership disclosures across all security types.

Market Context and Investor Considerations

SOPHiA Genetics SA is a precision diagnostics company that uses artificial intelligence and machine learning to analyze genomic data and support clinical decision-making. The company's business model centers on providing genetic testing and analysis solutions to healthcare providers, laboratories, and research institutions globally. As a NASDAQ-listed company, SOPHiA Genetics operates in the competitive genomics and diagnostic testing sector, where regulatory developments, clinical adoption, reimbursement decisions, and technological innovation significantly influence business performance and investor sentiment.

The immediate share price impact of this transaction was not clear from available public information at the time of filing. The sale of 5,000 shares by a single executive typically does not materially move a NASDAQ-listed company's stock price, though market conditions and overall trading volume can influence the impact of insider transactions. Investors monitoring insider activity often look at patterns over time rather than individual transactions, considering whether executives collectively are buying or selling shares, as such patterns may provide signals regarding management's confidence in the company's medium to longer-term trajectory.

Regulatory Compliance and Filing Requirements

The Form 4 filing is required under Section 16(a) of the Securities Exchange Act of 1934 for officers, directors, and beneficial owners of more than ten percent of a company's equity securities. Philippe Menu's status as an officer of SOPHiA Genetics SA triggers his obligation to file Form 4 reports whenever he acquires, disposes of, or materially changes his beneficial ownership of the company's securities. The SEC enforces strict compliance with these reporting requirements, and the form itself includes a warning that intentional misstatements or omissions of facts constitute federal criminal violations under 18 U.S.C. § 1001 and 15 U.S.C. § 78ff(a).

The filing was submitted in accordance with standard SEC procedures, with Menu's attorney-in-fact signing on his behalf. The form indicates that the reporting person checks a box confirming that the transaction was made pursuant to a Rule 10b5-1 trading plan, which is the legally required disclosure mechanism for certifying that an insider sale was executed under a pre-arranged, legally compliant schedule. This certification is important for both the company and regulators in tracking insider trading compliance and ensuring that officer and director transactions occur within appropriate regulatory frameworks designed to protect against conflicts of interest and market manipulation.